Kairos Pharma, LTD.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Market Information
Our common stock is listed on the NYSE American LLC, or NYSE American, under the symbol “KAPA.”
Holders
As of March 31, 2026, we had 48 holders of record of our common stock and 21,411,198 shares of common stock issued and outstanding. This number of holders of record does not represent the actual number of beneficial owners of our common shares because shares are frequently held in “street name” by securities dealers and others for the benefit of individual owners who have the right to vote their shares.
Dividends
We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant. In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into.
Securities authorized for issuance under equity compensation plans.
The following table provides information about the Company’s common stock that may be issued under the Company’s 2023 Equity Incentive Plan as of December 31, 2025.
| Plan Category | Number of securities to be issued upon exercise or vesting of outstanding options, warrants, rights and restricted stock units | Weighted-average exercised price of outstanding options, warrants, rights and restricted stock units | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column) |
|---|---|---|---|
| Equity compensation plans approved by stockholders | 772,605 | $1.05 | 877,395 |
| Equity compensation plans not approved by security holders | - | - | - |
| Total | 772,605 | 1.05 | 877,395 |
Recent Sales of Unregistered Securities
See below “Recent Developments - January 2025 PIPE Offering.”
Issuer Purchases of Equity Securities
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.